Cargando…

Anti-acid therapy in idiopathic pulmonary fibrosis: insights from the INPULSIS® trials

BACKGROUND: The benefits and risks of anti-acid medication in patients with idiopathic pulmonary fibrosis (IPF) remain a topic of debate. We investigated whether use of anti-acid medication at baseline was associated with differences in the natural course of disease or influenced the treatment effec...

Descripción completa

Detalles Bibliográficos
Autores principales:	Costabel, Ulrich, Behr, Jürgen, Crestani, Bruno, Stansen, Wibke, Schlenker-Herceg, Rozsa, Stowasser, Susanne, Raghu, Ganesh
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2018
Materias:	Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6122773/ https://www.ncbi.nlm.nih.gov/pubmed/30176872 http://dx.doi.org/10.1186/s12931-018-0866-0

Ejemplares similares

Long‐term treatment with nintedanib in Asian patients with idiopathic pulmonary fibrosis: Results from INPULSIS®‐ON
por: Song, Jin Woo, et al.
Publicado: (2019)

Psychometric properties of the St George’s Respiratory Questionnaire in patients with idiopathic pulmonary fibrosis: insights from the INPULSIS trials
por: Swigris, Jeffrey J, et al.
Publicado: (2018)

First Data on Efficacy and Safety of Nintedanib in Patients with Idiopathic Pulmonary Fibrosis and Forced Vital Capacity of ≤50 % of Predicted Value
por: Wuyts, Wim A., et al.
Publicado: (2016)

Health-related quality of life and symptoms in patients with IPF treated with nintedanib: analyses of patient-reported outcomes from the INPULSIS® trials
por: Kreuter, Michael, et al.
Publicado: (2020)

Differing severities of acute exacerbations of idiopathic pulmonary fibrosis (IPF): insights from the INPULSIS® trials
por: Kreuter, Michael, et al.
Publicado: (2019)

Analysis of body mass index, weight loss and progression of idiopathic pulmonary fibrosis
por: Jouneau, Stéphane, et al.
Publicado: (2020)

Long-term treatment of patients with idiopathic pulmonary fibrosis with nintedanib: results from the TOMORROW trial and its open-label extension
por: Richeldi, Luca, et al.
Publicado: (2018)

Efficacy and safety of nintedanib in patients with advanced idiopathic pulmonary fibrosis
por: Richeldi, Luca, et al.
Publicado: (2020)

The changing treatment landscape in idiopathic pulmonary fibrosis
por: Costabel, Ulrich
Publicado: (2015)

Nintedanib in patients with idiopathic pulmonary fibrosis and preserved lung volume
por: Kolb, Martin, et al.
Publicado: (2017)

Idiopathic pulmonary fibrosis in 2011: key updates on guidelines and therapeutics Concluding remarks
por: Costabel, Ulrich
Publicado: (2013)

Safety and survival data in patients with idiopathic pulmonary fibrosis treated with nintedanib: pooled data from six clinical trials
por: Lancaster, Lisa, et al.
Publicado: (2019)

Efficacy and safety of nintedanib in patients with idiopathic pulmonary fibrosis who are elderly or have comorbidities
por: Glaspole, Ian, et al.
Publicado: (2021)

Idiopathic pulmonary fibrosis in 2011: key updates on guidelines and therapeutics
por: Costabel, U, et al.
Publicado: (2013)

Idiopathic pulmonary fibrosis: current treatment options and critical appraisal of nintedanib
por: Bonella, Francesco, et al.
Publicado: (2015)

Pharmacotherapy for idiopathic pulmonary fibrosis: current landscape and future potential
por: Raghu, Ganesh
Publicado: (2017)

Parametric Time‐to‐Event Model for Acute Exacerbations in Idiopathic Pulmonary Fibrosis
por: Tang, Fei, et al.
Publicado: (2020)

Nintedanib and Sildenafil in Patients with Idiopathic Pulmonary Fibrosis and Right Heart Dysfunction. A Prespecified Subgroup Analysis of a Double-Blind Randomized Clinical Trial (INSTAGE)
por: Behr, Jürgen, et al.
Publicado: (2019)

Mode of action of nintedanib in the treatment of idiopathic pulmonary fibrosis
por: Wollin, Lutz, et al.
Publicado: (2015)

A New Tool to Assess Quality of Life in Patients with Idiopathic Pulmonary Fibrosis or Non-specific Interstitial Pneumonia
por: Kirsten, Detlef, et al.
Publicado: (2021)

Physiology of the lung in idiopathic pulmonary fibrosis
por: Plantier, Laurent, et al.
Publicado: (2018)

Effects of nintedanib in patients with idiopathic pulmonary fibrosis by GAP stage
por: Ryerson, Christopher J., et al.
Publicado: (2019)

Guidelines or guidance for better idiopathic pulmonary fibrosis management?
por: Behr, Jürgen
Publicado: (2016)

Cardiovascular safety of nintedanib in subgroups by cardiovascular risk at baseline in the TOMORROW and INPULSIS trials
por: Noth, Imre, et al.
Publicado: (2019)

Antifibrotic therapy for fibrotic lung disease beyond idiopathic pulmonary fibrosis
por: Collins, Bridget F., et al.
Publicado: (2019)

Efficacy and Safety of Pirfenidone in Advanced Versus Non-Advanced Idiopathic Pulmonary Fibrosis: Post-Hoc Analysis of Six Clinical Studies
por: Behr, Jürgen, et al.
Publicado: (2023)

Idiopathic Pulmonary Fibrosis in Elderly Patients: Analysis of the INSIGHTS-IPF Observational Study
por: Leuschner, Gabriela, et al.
Publicado: (2020)

Effect of statins on disease-related outcomes in patients with idiopathic pulmonary fibrosis
por: Kreuter, Michael, et al.
Publicado: (2017)

Effect of pirfenidone in patients with more advanced idiopathic pulmonary fibrosis
por: Costabel, Ulrich, et al.
Publicado: (2019)

The European IPF registry (eurIPFreg): baseline characteristics and survival of patients with idiopathic pulmonary fibrosis
por: Guenther, Andreas, et al.
Publicado: (2018)

Ongoing challenges in pulmonary fibrosis and insights from the nintedanib clinical programme
por: Valenzuela, Claudia, et al.
Publicado: (2020)

Lung function in idiopathic pulmonary fibrosis - extended analyses of the IFIGENIA trial
por: Behr, Jürgen, et al.
Publicado: (2009)

Treatment patterns, resource use and costs of idiopathic pulmonary fibrosis in Spain – results of a Delphi Panel
por: Morell, Ferran, et al.
Publicado: (2016)

Pirfenidone safety and adverse event management in idiopathic pulmonary fibrosis
por: Lancaster, Lisa H., et al.
Publicado: (2017)

Potential of nintedanib in treatment of progressive fibrosing interstitial lung diseases
por: Wollin, Lutz, et al.
Publicado: (2019)

Treatment of idiopathic pulmonary fibrosis: a network meta-analysis
por: Rochwerg, Bram, et al.
Publicado: (2016)

Chaotic activation of developmental signalling pathways drives idiopathic pulmonary fibrosis
por: Froidure, Antoine, et al.
Publicado: (2020)

Safety, tolerability and appropriate use of nintedanib in idiopathic pulmonary fibrosis
por: Corte, Tamera, et al.
Publicado: (2015)

No association between human herpesvirus or herpesvirus saimiri and idiopathic pulmonary fibrosis
por: Le Hingrat, Quentin, et al.
Publicado: (2020)

Phase 2 trial to assess lebrikizumab in patients with idiopathic pulmonary fibrosis
por: Maher, Toby M., et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_pdnovtose0rlb0o57879ecpnsr